Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29783095 | 1.00 | HTR2A (0.48) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL1287466 | 0.83 | HTR1A (0.37) | HTR2AHTR2CCA2MAPTGAA | |
| SCHEMBL8926 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL29792655 | 0.82 | TAAR1 (0.52) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL172225 | 0.82 | HTR2A (0.46) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL2904854 | 0.81 | IDO1 (0.55) | IDO1TAAR1L3MBTL1CA12CA1 | |
| SCHEMBL16805903 | 0.81 | GABRA1 (0.47) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL3533385 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| Bromide SCHEMBL15741709 | 0.80 | TAAR1 (0.50) | HTR2AHTR2CIDO1TAAR1L3MBTL1 | |
| SCHEMBL422832 | 0.80 | HTR2A (0.44) | HTR2AHTR2CIDO1TAAR1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4644390-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | Beyang Therapeutics Co., Ltd. (CN) | 2025-11-05 | — | — | EP | disclosed |
| US-20240409542-A1 | NOVEL COMPOUNDS | SITRYX THERAPEUTICS LIMITED (GB) | 2024-12-12 | — | — | US | disclosed |
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | J. MICHAEL BISHOP INSTITUTE OF CANCER RESEARCH (CN) | 2024-08-15 | — | — | US | disclosed |
| WO-2024140850-A1 | PROTEIN TYROSINE KINASE INHIBITOR AND MEDICAL USE THEREOF | 苏州必扬医药科技有限公司 | 2024-07-04 | — | — | WO | disclosed |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | KANAPH THERAPEUTICS INC. (KR) | 2024-06-13 | — | — | US | disclosed |
| CN-118139864-A | New compounds | 西特瑞治疗有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| CN-109069514-B | Antibacterial compound and application thereof | 结核病药物开发全球联盟公司 | 2023-12-29 | — | — | CN | disclosed |
| EP-4277897-A1 | FUSED AZEPINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | Chengdu Anticancer Bioscience, Ltd. (CN) | 2023-11-22 | — | — | EP | disclosed |
| CN-116710442-A | Compounds, compositions and methods for treating disorders | 成都安泰康赛生物科技有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-2802592-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| WO-2013104703-A1 | SUBSTITUTED ANNULATED PYRIMIDINES AND TRIAZINES, AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-07-18 | — | — | WO | disclosed |
| EP-1527051-B1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| US-8106063-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2012-01-31 | — | — | US | disclosed |
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ASTRAZENECA AB (SE) | 2010-03-11 | — | — | US | disclosed |
| US-7582644-B2 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2009-09-01 | — | — | US | disclosed |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ASTRAZENECA AB (SE) | 2006-02-02 | — | — | US | disclosed |
| EP-1527051-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2005-05-04 | — | — | EP | disclosed |
| WO-2004011443-A1 | PYRIMIDYL SULPHONE AMIDE DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063079-A1 | Pyrimidyl Sulphone Amide Derivatives as Chemokine Receptor Modulators | ACKR3, GPR17, CCL11 | HTR2A 1669/4885HTR2C 1992/4885IDO1 708/4885 |
| US-20240270695-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS | CYP27A1, PNLIP, GOT2 | HTR2A 1878/4885HTR2C 1661/4885IDO1 3404/4885 |
| US-20240189306-A1 | SHP2 INHIBITOR AND USE THEREOF | PTPN1, PTPN5, PTPN2 | HTR2A 4330/4885HTR2C 4638/4885IDO1 952/4885 |
| US-20240409542-A1 | NOVEL COMPOUNDS | CD47, GPR119, LRBA | HTR2A 4273/4885HTR2C 4316/4885IDO1 611/4885 |
| US-20060025432-A1 | Pyrimidyl sulphone amide derivatives as chemokine receptor modulators | ACKR3, GPR17, CCL11 | HTR2A 1669/4885HTR2C 1992/4885IDO1 708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.